NEO-TRA1 / Neoleukin Therap - LARVOL DELTA

NEO-TRA1: A CD25-Targeted De Novo non-Alpha Agonist of the IL-2 Receptor Selectively Expands Regulatory T Cells (ASH 2022) - "NEO-TRA1 exhibits potent expansion of Treg populations within primary human samples and in humanized mouse models. The observed profile of STAT5 phosphorylation demonstrates selective activation of Tregs over other lymphocyte populations. NEO-TRA1 is the first Treg agonist based on de novo protein design."

Graft versus Host Disease • Immunology • Inflammation • CD4 • CD8 • FCGR2A • FCGR2B • FOXP3 • IL2 • IL2RA • IL7R • STAT5

Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) - "Neoleukin Therapeutics...presented data on NEO-TRA1, a precision-tuned agonist of the IL-2 receptor beta and gamma subunits that is targeted to and selectively expands inhibitory T-regulatory cells. The data are being disclosed today as an oral presentation at the American Society of Hematology (ASH) Annual Meeting. The presentation highlights two important features of Neoleukin’s de novo protein technology: 1) the ability to target de novo cytokine mimetics to specific cell types, i.e. T-regulatory cells; and 2) precision-tuned de novo payloads that have minimal effects on non-targeted cells. By separating the targeting domain from the cytokine receptor agonist, Neoleukin scientists have created a potentially modular system for the cis-targeting of de novo proteins to specific immune cell subsets."

Preclinical • Immunology • Inflammation

Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) - "Neoleukin Therapeutics...announced an oral presentation at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 10-13, 2022 in New Orleans, Louisiana."

Preclinical • Graft versus Host Disease • Immunology